Modulation of IL ‐23 Signaling With Guselkumab in Biologic‐Naïve Patients Versus TNF Inhibitor‐Inadequate Responders With Active Psoriatic Arthritis

ConclusionGuselkumab modulates IL-23 signaling and provides consistent pharmacodynamic effects in both biologic-na ïve and TNFi-IR PsA patients. Significantly elevated baseline IL-22, TNFα, and BD-2 levels and associations between baseline IL-22, IL-17A, and BD-2 levels and skin responses with guselkumab suggest greater dysregulation of IL-23/Th17 signaling in TNFi-IR patients.

Source: Arthritis and Rheumatology - January 23, 2024 Category: Rheumatology Authors: Stefan Siebert, Laura C. Coates, Georg Schett, Siba P. Raychaudhuri, Warner Chen, Sheng Gao, Loqmane Seridi, Soumya D. Chakravarty, May Shawi, Frederic Lavie, Mohamed Sharaf, Miriam Zimmermann, Alexa P. Kollmeier, Xie L. Xu, Proton Rahman, Tags: Full Length Source Type: research